CD markers polymorphisms as prognostic biomarkers in hematological malignancies

  • Saeid Shahrabi Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of.
  • Majid Ghanavat Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of.
  • Masumeh Maleki Behzad Blood Transfusion Research Center, High Institute for Research and Education in Transfusion, Hamadan; Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Daryush Purrahman Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Najmaldin Saki | najmaldinsaki@gmail.com Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.

Abstract

The clusters of differentiation (CD) are surface molecules used for immunophenotyping of cells. The expression of CD markers is widely used to classify hematological malignancies, including leukemia and lymphoma. Single nucleotide polymorphisms (SNPs) are crucial genetic changes that can be associated with abnormal expression and function of CD markers. In this paper, we assess the prognostic effect of CD markers’ SNPs in hematological malignancies. Materials and methods and relevant literature was identified by a PubMed search (2001-2019) of English language papers using the following terms: ‘polymorphism’, ‘CD marker’, ‘leukemia’, ‘lymphoma’, ‘prognosis’, ‘CD marker’, and ‘polymorphism’. Many studies have demonstrated the effects of CD markers’ polymorphisms on risk of hematological malignancies. Also, SNPs of CD markers can be related with clinicopathological features, invasiveness, and response to therapy of these disorders. Considering the importance of SNPs in the expressions of CD markers, these genetic changes could be used as potential prognostic biomarkers in hematological malignancies. It is hoped that the evaluation of SNPs in CD markers will enable early diagnosis, prognosis, and detection of response to treatment. However, better understanding of SNPs in CD markers that are involved in hematological malignancies requires further studies on different populations of the worldwide.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-07-14
Info
Issue
Section
Reviews
Keywords:
Leukemia, lymphoma, CD marker, polymorphism, prognosis.
Statistics
  • Abstract views: 38

  • PDF: 18
  • HTML: 0
How to Cite
Shahrabi, S., Ghanavat, M., Maleki Behzad, M., Purrahman, D., & Saki, N. (2020). CD markers polymorphisms as prognostic biomarkers in hematological malignancies. Oncology Reviews, 14(2). https://doi.org/10.4081/oncol.2020.466

Most read articles by the same author(s)